Ensysce Biosciences Inc Cash Flow-to-Debt Ratio
Ensysce Biosciences Inc cash flow-to-debt ratio. Ensysce Biosciences Inc (ENSC) has a Cash Flow-to-Debt Ratio of -0.48x as of June 2026, meaning its operating cash flow of $-1.96 Million could theoretically repay 0% of its total liabilities ($4.07 Million) in one year. Check how high is Ensysce Biosciences Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Ensysce Biosciences Inc (2017–2025)
Cash flow-to-debt ratio of Ensysce Biosciences Inc from 2017 to 2025. Historical debt coverage capacity for Ensysce Biosciences Inc across 9 annual periods. Check Ensysce Biosciences Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Ensysce Biosciences Inc Cash Flow-to-Debt Ratio by Year (2017–2025)
Ensysce Biosciences Inc cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Ensysce Biosciences Inc. For the full cash flow conversion analysis, see Ensysce Biosciences Inc cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.71x | $-7.81 Million | $4.57 Million | ▲ +49.5% |
| 2024 | -3.38x | $-7.50 Million | $2.22 Million | ▼ -5.4% |
| 2023 | -3.21x | $-10.78 Million | $3.36 Million | ▼ -77.9% |
| 2022 | -1.80x | $-17.89 Million | $9.91 Million | ▼ -437.9% |
| 2021 | -0.34x | $-8.24 Million | $24.58 Million | ▼ -88.5% |
| 2020 | -0.18x | $-1.25 Million | $7.01 Million | ▼ -116.7% |
| 2019 | 1.06x | $10.99 Million | $10.34 Million | ▲ +739.0% |
| 2018 | -0.17x | $-1.24 Million | $7.44 Million | ▼ -373.0% |
| 2017 | -0.04x | $-251.83K | $7.16 Million | — |